HanAll Biopharma's 'Venorondi Tablets' and 'Alcarbon Plus Tablets' [Photo provided by HanAll Biopharma]

HanAll Biopharma's 'Venorondi Tablets' and 'Alcarbon Plus Tablets' [Photo provided by HanAll Biopharma]

View original image

[Asia Economy Reporter Lee Chun-hee] HanAll Biopharma announced on the 1st that it has launched ‘Venorondi Tablets,’ a treatment for hemorrhoids and varicose veins with increased ingredient content, and ‘Alcarbon Plus Tablets,’ which can supplement calcium and vitamin D at once.


Venorondi is a product that doubles the diosmin content of HanAll Biopharma’s existing vascular strengthening agent ‘Venoron Capsules’ (active ingredient diosmin). Diosmin is a component derived from natural substances in plants and is known to be effective in improving symptoms related to venous insufficiency such as pain and itching caused by hemorrhoids, as well as leg heaviness and pain.


Venorondi contains 600 mg, the highest dosage among diosmin-containing drugs in Korea, and improves medication convenience by reducing the oral administration from twice a day to once a day for relieving venous insufficiency. For hemorrhoid treatment, it can be taken 2 to 3 times a day (1200?1800 mg) with meals. As an insurance-covered product, it lowers the patient’s drug cost burden.


They also introduced ‘Alcarbon Plus,’ which supports bone health with one tablet a day. One tablet daily supplements 500 mg of calcium and 1000 IU of vitamin D, the daily recommended amount. Compared to HanAll Biopharma’s existing calcium supplement ‘Alcarbon Tablets,’ the calcium content is increased to help patients with insufficient calcium intake, such as the elderly, pregnant, and breastfeeding women, easily replenish their nutrition.



Jung Seung-won, CEO of HanAll Biopharma, said, “Through Venorondi and Alcarbon Plus, we expect to improve medication convenience for many patients as well as reduce their economic burden,” adding, “We will continue to strive to develop products that meet the needs of medical professionals and patients.”


This content was produced with the assistance of AI translation services.

© The Asia Business Daily(www.asiae.co.kr). All rights reserved.

Today’s Briefing